Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

@article{Chamberlain2006EarlyNF,
  title={Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma},
  author={Marc C Chamberlain and Michael J. Glantz and Lisa M Chalmers and Alixis Van Horn and Andrew E. Sloan},
  journal={Journal of Neuro-Oncology},
  year={2006},
  volume={82},
  pages={81-83}
}
Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen. 
Combined temozolomide and radiation as an initial treatment for anaplastic glioma
TLDR
This retrospective study aimed to compare the outcome of patients who had combined TMZ and RT with those who had RT alone for the initial treatment of anaplastic glioma in the authors' centers.
Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
TLDR
The occurrence of early pseudo‐progression was retrospectively assessed in a cohort of malignant glioma patients treated with RT/TMZ.
Salvage chemotherapy with CPT‐11 for recurrent temozolomide‐refractory anaplastic astrocytoma
The primary objective of this prospective phase 2 study of CPT‐11 in adult patients with recurrent temozolomide‐refractory anaplastic astrocytoma (AA) was to evaluate 6‐month progression‐free
Early post‐treatment pseudo‐progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: A retrospective analysis
Introduction: To evaluate the incidence and impact of early post‐chemoradiation (cRT) ‘pseudoprogression’ (PsPD) amongst glioblastoma multiforme (GBM) patients treated with the current standard of
Distinction of pseudo progression and progression in GBM patients taking adjuvant and concomitant Temozolomide with radiotherapy via perfusion MRI
TLDR
Distinction of pseudo progression and progression in GBM patients taking adjuvant and concomitant Temozolomide with radiotherapy via perfusion MRI is distinguished.
Pseudoprogression and treatment effect.
Defining pseudoprogression in glioblastoma multiforme
TLDR
Pseudoprogression is a frequent phenomenon observed since the introduction of postoperative therapy with radiotherapy and temozolomide (RT/TMZ) in glioblastoma multiforme patients and its impact on therapy and outcome remains poorly defined.
Temozolomide in malignant gliomas: current use and future targets
TLDR
Developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ—mechanism of action, scheduling and strategies for overcoming resistance are summarized.
From Expert Review of Anticancer Therapy
TLDR
New therapeutic strategies, such as targeted therapies and anti-angiogenic treatments that appear promising with regard to improving the results at the time of recurrence are discussed.
Treatment options for recurrent glioblastoma: pitfalls and future trends
TLDR
New therapeutic strategies, such as targeted therapies and anti-angiogenic treatments that appear promising with regard to improving the results at the time of recurrence are discussed.
...
...

References

SHOWING 1-10 OF 10 REFERENCES
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas
TLDR
The availability of temozolomide (TMZ), a new alkylating agent with antiglioma efficacy, offers another potential therapeutic option for elderly patients with malignant gliomas.
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
TLDR
It is concluded that patients with progressive lesions within 3 months after radiotherapy should not be eligible for phase II trials on recurrent glioma.
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
  • R. Stupp, P. Dietrich, S. Leyvraz
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
This regimen of concomitant chemoradiotherapy followed by adjuvant chemotherapy may prolong the survival of patients with glioblastoma.
Neurologic complications of radiation therapy.
Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.
TLDR
This study of malignant glioma patients used a non-parametric statistical technique to examine the associations of both pretreatment patient and tumor characteristics and treatment-related variables with survival duration and permits examination of the interaction between prognostic variables not possible with other forms of multivariate analysis.
Brain tumors.
TLDR
This volume provides examples of over 100 brain tumors, running the gamut from the very common to the rare, offering the opportunity to review both the basics for the beginner or relatively inexperienced pathologist and also offers experienced pathologists the chance to see some of the rare entities.
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
  • 2005
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
TLDR
The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
J Neurooncol
  • J Neurooncol